Allogene Therapeutics Inc

Market cap: $586,749,212

Exchange: NAS

Sector: Health Technology

Share
Tweet

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Key Statistics

Company Name

Allogene Therapeutics Inc

Average Volume (10 days)

1,938,329

Average Volume (30 days)

1,662,480

Moving Average (50 days)

$4.37

Moving Average (200 days)

$3.54

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

-1.7929

Market Cap

586,749,212

Shares Outstanding

169,091,992

52-Week High Split Adjust Only

6.89

52-Week Low Split Adjust Only

2.23

Employee Count

380

Beta

1.6613

Next Earnings Date

2024-05-01

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

-0.09%

Past 30 days

-0.22%

Past 3 months

0.12%

Past 6 months

0.16%

Past year

-0.3%

Past 2 years

-0.56%

Past 5 years

-0.87%

Max % Change

-0.86%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
Allogene Therapeutics IncALLOn/an/a-13.0n/an/a
Peer AvgN/An/an/a-8.0n/an/a
Ocular Therapeutix IncOCULn/an/a-19.1n/an/a
Oncocyte CorporationOCXn/an/a-13.1n/an/a
Oragenics Inc.OGENn/an/an/an/an/a